A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN

Trial Profile

A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs TEV 45478 (Primary)
  • Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NASH
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 02 Jan 2018 Planned End Date changed from 1 Feb 2018 to 28 Feb 2018.
    • 02 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 31 Jan 2018.
    • 02 Jan 2018 Status changed from suspended to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top